Contrast-Enhanced MRI for Leptomeningeal Disease

This trial aims to determine if gadopiclenol, a new contrast agent used during MRI scans, can help detect early signs of leptomeningeal disease (LMD). LMD is a serious condition where cancer spreads to the membranes surrounding the brain and spinal cord. Participants will undergo specialized MRI scans to assess whether this contrast agent provides clearer images than standard methods. The trial seeks individuals with solid tumors who have had unclear MRI results for LMD and negative fluid tests from around the brain. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could enhance early detection methods for LMD.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies have shown that both Gadavist and VUEWAY are safe as contrast agents in MRI scans. Researchers tested Gadavist in over 7,713 people, including children, and found it generally well tolerated. Only about 0.84% of patients reported side effects, mostly mild.

VUEWAY, also known as gadopiclenol, underwent safety evaluation in studies with over 1,083 patients, demonstrating a high level of safety. Ongoing monitoring after its release continues to confirm its safety, with no major health issues reported.

Researchers are excited about this trial because it explores a new MRI technique using gadopiclenol, a contrast agent that may offer clearer imaging for detecting leptomeningeal disease (LMD) in the brain. Unlike standard MRI contrast agents, gadopiclenol could provide enhanced visualization of the brain’s membranes, potentially leading to earlier and more accurate diagnosis of LMD. This could be a game-changer for patients, as early detection is crucial for managing this condition effectively. By improving the sensitivity and specificity of MRI scans, this approach might significantly impact treatment planning and outcomes for those affected by LMD.

This trial will compare two contrast dyes for MRI scans: gadobutrol (Gadavist) and gadopiclenol (VUEWAY). Studies have shown that Gadavist effectively enhances MRI scans, allowing doctors to see lesions and blood flow in the brain and spine more clearly. Research indicates that it provides reliable diagnostic information for various conditions. In contrast, VUEWAY has demonstrated even better contrast at half the dose of Gadavist. Evidence suggests it improves the detection of brain and spine lesions, making it a promising option for early diagnosis of conditions like leptomeningeal disease. Both dyes are considered safe, supporting their use in MRI for clearer imaging results.¹⁵⁶⁷⁸